{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T12:55:50Z","timestamp":1765976150971,"version":"3.40.3"},"publisher-location":"Cham","reference-count":27,"publisher":"Springer International Publishing","isbn-type":[{"type":"print","value":"9783319596587"},{"type":"electronic","value":"9783319596594"}],"license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017]]},"DOI":"10.1007\/164_2017_24","type":"book-chapter","created":{"date-parts":[[2017,4,27]],"date-time":"2017-04-27T06:24:05Z","timestamp":1493274245000},"page":"109-129","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Heart Failure Guidelines on Pharmacotherapy"],"prefix":"10.1007","author":[{"given":"Lampros","family":"Papadimitriou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carine E.","family":"Hamo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,4,28]]},"reference":[{"issue":"10","key":"24_CR26","doi-asserted-by":"publisher","first-page":"e146","DOI":"10.1161\/CIR.0000000000000485","volume":"135","author":"EJ Benjamin","year":"2017","unstructured":"Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, de Ferranti SD, Floyd J, Fornage M, Gillespie C, Isasi CR, Jimenez MC, Jordan LC, Judd SE, Lackland D, Lichtman JH, Lisabeth L, Liu S, Longenecker CT, Mackey RH, Matsushita K, Mozaffarian D, Mussolino ME, Nasir K, Neumar RW, Palaniappan L, Pandey DK, Thiagarajan RR, Reeves MJ, Ritchey M, Rodriguez CJ, Roth GA, Rosamond WD, Sasson C, Towfighi A, Tsao CW, Turner MB, Virani SS, Voeks JH, Willey JZ, Wilkins JT, Wu JH, Alger HM, Wong SS, Muntner P (2017) Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation 135(10):e146\u2013e603","journal-title":"Circulation"},{"key":"24_CR2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","volume":"353","author":"CIBIS-II Investigators and Committees","year":"1999","unstructured":"CIBIS-II Investigators and Committees (1999) The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet (London, England) 353:9\u201313","journal-title":"Lancet (London, England)"},{"key":"24_CR3","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1056\/NEJMoa010713","volume":"345","author":"JN Cohn","year":"2001","unstructured":"Cohn JN, Tognoni G (2001) A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345:1667\u20131675","journal-title":"N Engl J Med"},{"key":"24_CR4","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","volume":"316","author":"The CONSENSUS Trial Study Group","year":"1987","unstructured":"The CONSENSUS Trial Study Group (1987) Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril survival study (CONSENSUS). N Engl J Med 316:1429\u20131435","journal-title":"N Engl J Med"},{"issue":"9266","key":"24_CR27","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/S0140-6736(00)04560-8","volume":"357","author":"HJ Dargie","year":"2001","unstructured":"Dargie HJ (2001) Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 357(9266):1385\u201390","journal-title":"Lancet"},{"issue":"Suppl 2","key":"24_CR5","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2165\/00003495-200767002-00003","volume":"67","author":"D DiFrancesco","year":"2007","unstructured":"DiFrancesco D, Borer JS (2007) The funny current: cellular basis for the control of heart rate. Drugs 67(Suppl 2):15\u201324","journal-title":"Drugs"},{"key":"24_CR6","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1093\/eurheartj\/ehi115","volume":"26","author":"MD Flather","year":"2005","unstructured":"Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, Cohen-Solal A, Dumitrascu D, Ferrari R, Lechat P, Soler-Soler J, Tavazzi L, Spinarova L, Toman J, Bohm M, Anker SD, Thompson SG, Poole-Wilson PA (2005) Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26:215\u2013225","journal-title":"Eur Heart J"},{"key":"24_CR7","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1001\/jama.1995.03520420066040","volume":"273","author":"R Garg","year":"1995","unstructured":"Garg R, Yusuf S (1995) Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE inhibitor trials. JAMA 273:1450\u20131456","journal-title":"JAMA"},{"key":"24_CR8","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","volume":"362","author":"JJ McMurray","year":"2003","unstructured":"McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S, Pfeffer MA (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-added trial. Lancet (London, England) 362:767\u2013771","journal-title":"Lancet (London, England)"},{"key":"24_CR9","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1053\/euhj.1997.0839","volume":"19","author":"The NETWORK Investigators","year":"1998","unstructured":"The NETWORK Investigators (1998) Clinical outcome with enalapril in symptomatic chronic heart failure; a dose comparison. Eur Heart J 19:481\u2013489","journal-title":"Eur Heart J"},{"key":"24_CR10","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/postgradmedj-2016-134045","volume":"93","author":"C Orsborne","year":"2017","unstructured":"Orsborne C, Chaggar PS, Shaw SM, Williams SG (2017) The renin-angiotensin-aldosterone system in heart failure for the non-specialist: the past, the present and the future. Postgrad Med J 93:29\u201337","journal-title":"Postgrad Med J"},{"key":"24_CR11","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1161\/01.CIR.100.23.2312","volume":"100","author":"M Packer","year":"1999","unstructured":"Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, Ryden L, Thygesen K, Uretsky BF, ATLAS Study Group (1999) Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 100:2312\u20132318","journal-title":"Circulation"},{"key":"24_CR12","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1161\/01.CIR.0000035653.72855.BF","volume":"106","author":"M Packer","year":"2002","unstructured":"Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Staiger C, Holcslaw TL, Amann-Zalan I, DeMets DL (2002) Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 106:2194\u20132199","journal-title":"Circulation"},{"key":"24_CR13","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1056\/NEJMoa032292","volume":"349","author":"MA Pfeffer","year":"2003","unstructured":"Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM (2003) Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349:1893\u20131906","journal-title":"N Engl J Med"},{"key":"24_CR14","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J, Randomized Aldactone Evaluation Study Investigators (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341:709\u2013717","journal-title":"N Engl J Med"},{"key":"24_CR15","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","volume":"370","author":"B Pitt","year":"2014","unstructured":"Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O\u2019Meara E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, Yang S, McKinlay SM (2014) Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370:1383\u20131392","journal-title":"N Engl J Med"},{"key":"24_CR16","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 18:891\u2013975","journal-title":"Eur J Heart Fail"},{"issue":"9377","key":"24_CR28","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0140-6736(03)13800-7","volume":"362","author":"PA Poole-Wilson","year":"2003","unstructured":"Poole-Wilson PA, Swedberg K, Cleland JG et al (2003) Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 362(9377):7\u201313","journal-title":"Lancet"},{"key":"24_CR17","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1056\/NEJM199108013250501","volume":"325","author":"The SOLVD Investigators","year":"1991","unstructured":"The SOLVD Investigators (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325:293\u2013302","journal-title":"N Engl J Med"},{"key":"24_CR18","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","volume":"376","author":"K Swedberg","year":"2010","unstructured":"Swedberg K, Komajda M, B\u00f6hm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L (2010) Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376:875\u2013885","journal-title":"Lancet"},{"key":"24_CR19","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1056\/NEJMoa042934","volume":"351","author":"AL Taylor","year":"2004","unstructured":"Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino R Jr, Ferdinand K, Taylor M, Adams K, Sabolinski M, Worcel M, Cohn JN (2004) Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 351:2049\u20132057","journal-title":"N Engl J Med"},{"key":"24_CR20","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1016\/j.jacc.2009.05.015","volume":"54","author":"F Triposkiadis","year":"2009","unstructured":"Triposkiadis F, Karayannis G, Giamouzis G, Skoularigis J, Louridas G, Butler J (2009) The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. J Am Coll Cardiol 54:1747\u20131762","journal-title":"J Am Coll Cardiol"},{"key":"24_CR21","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.cardfail.2016.07.001","volume":"22","author":"Writing Committee M","year":"2016","unstructured":"Writing Committee M, Acc\/Aha Task Force M (2016) 2016 ACC\/AHA\/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines and the Heart Failure Society of America. J Card Fail 22:659\u2013669","journal-title":"J Card Fail"},{"key":"24_CR22","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","volume":"62","author":"CW Yancy","year":"2013","unstructured":"Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL (2013a) 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 62:e147\u2013e239","journal-title":"J Am Coll Cardiol"},{"key":"24_CR23","doi-asserted-by":"publisher","first-page":"e240","DOI":"10.1161\/CIR.0b013e31829e8807","volume":"128","author":"CW Yancy","year":"2013","unstructured":"Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJV, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WHW, Tsai EJ, Wilkoff BL (2013b) 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association task force on practice guidelines. Circulation 128:e240\u2013e327","journal-title":"Circulation"},{"key":"24_CR24","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","volume":"362","author":"S Yusuf","year":"2003","unstructured":"Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J (2003) Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial. Lancet (London, England) 362:777\u2013781","journal-title":"Lancet (London, England)"},{"key":"24_CR25","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364:11\u201321","journal-title":"N Engl J Med"}],"container-title":["Handbook of Experimental Pharmacology","Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/164_2017_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T15:56:49Z","timestamp":1558022209000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/164_2017_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"ISBN":["9783319596587","9783319596594"],"references-count":27,"URL":"https:\/\/doi.org\/10.1007\/164_2017_24","relation":{},"ISSN":["0171-2004","1865-0325"],"issn-type":[{"type":"print","value":"0171-2004"},{"type":"electronic","value":"1865-0325"}],"subject":[],"published":{"date-parts":[[2017]]},"assertion":[{"value":"28 April 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}